Europe organ-on-chip market accounted for $6.9 million in 2020 and will grow by 32.2% annually over 2020-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments.
Highlighted with 33 tables and 51 figures, this 106-page report “Europe Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe organ-on-chip market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces


The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe organ-on-chip market in every aspect of the classification from perspectives of Offering, Organ Type, Material, Application, End User, and Country.

Based on Offering, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

  • Chips
  • Service



Based on Organ Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

  • Liver-on-a-Chip
  • Heart-on-a-Chip
  • Lung-on-a-Chip
  • Kidney-on-a-Chip
  • Brain-on-a-Chip
  • Skin-on-a-Chip
  • Vessels-on-a-Chip
  • Other Organ Types



Based on Material, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

  • Polymers
  • Glass
  • Silicon



Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

  • Drug Discovery
  • Toxicology Research
  • Other Applications



Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Cosmetics Industry
  • Other End Users



Geographically, the following national/local markets are fully investigated:

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)


For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Organ Type, Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AxoSim Inc.
BiomimX SRL
Cherry Biotech
CN Bio Innovations, Ltd.
Emulate Inc.
Hurel Corporation
InSphero AG
Kirkstall, Ltd.
MIMETAS BV
Nortis Inc.
Organovo, Inc.
SynVivo, Inc.
Tara Biosystems Inc.
TissUse GmbH
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)